
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE information, and to apply for credit, please visit us at PeerView.com/VPZ865. CME/CPE credit will be available until December 10, 2025.
Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.
4.3
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE information, and to apply for credit, please visit us at PeerView.com/VPZ865. CME/CPE credit will be available until December 10, 2025.
Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.
129 Listeners
6 Listeners
31 Listeners
3 Listeners
3 Listeners
10 Listeners
5 Listeners
28 Listeners
9 Listeners
3 Listeners
2 Listeners
5 Listeners
3 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
317 Listeners
41 Listeners
2 Listeners
115 Listeners
2 Listeners
488 Listeners
56 Listeners
43 Listeners
21 Listeners
321 Listeners
53 Listeners
10 Listeners
166 Listeners
38 Listeners